Chintan P. Shah, MD, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2010 | Maharaja Sayajirao University, Gujarat, IN, MD |
Postgraduate Training
| 2018-2021 | Clinical Fellowship, Hematology/Oncology, University of Florida, Gainesville, Florida |
| 2011-2014 | Clinical Residency, Western Michigan University, Kalamazoo, Michigan |
Board Certifications
| 2024 | DEA |
| 2021 | Medical Oncology |
| 2021 | Hematology |
| 2015 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Regional Director, Cleveland Clinic Cancer Center, Mansfield, OH, 2022 - 2023
Associate Staff, Cleveland Clinic Cancer Center, Mansfield, OH, 2021 - 2023
Fellow, Department of Hematology/Oncology, University of Florida, Gainesville, FL, 2018 - 2021
Clinical Assistant Professor, Department of General Internal Medicine, University of Florida, Gainesville, FL, 2016 - 2018
Fellow, Borgess Medical Center, Kalamazoo, MI, 2014 - 2016
Resident, Department of School of Medicine, Western Michigan University Homer, Stryker MD, Kalamazoo, MI, 2011 - 2014
Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2011
Rotary Internship, S.S G. Hospital University Baroda, Gujarat, 2008 - 2010
Institutional Committee Activities
Member, Beacon Committee, 2023 - Present
Member, Infusion Room Safety Committee, 2022 - 2023
Member, Sepsis Committee, 2016 - 2018
Member, Research Committee, 2016 - 2018
Blood Bank Member, Transfusion Committee, 2013 - 2014
Honors & Awards
| 2024 | Outstanding Teacher Award, The University of Texas Medical Branch |
| 2021 | Humanism Award, University of Florida |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Varkoly, K, Tan, S, Beladi, R, Fonseca, D, Zanetti, IR, Kraberger, S, Shah, CP, Yaron, JR, Zhang, L, Juby, M, Fath, A, Ambadapadi, S, House, M, Maranian, P, Pepine, CJ, Varsani, A, Moreb, JS, Schultz-Cherry, S, Lucas, AR. RNA Virus Gene Signatures Detected in Patients with Cardiomyopathy After Chemotherapy; A Pilot Study. Frontiers in Cardiovascular Medicine 9, 2022. PMID: 35360008.
- Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of Clinical Factors and Recent Anticancer Therapy with COVID-19 Severity among Patients with Cancer: A report from the COVID-19 and Cancer Consortium. Ann Oncol 32(6):787-800, 2021. e-Pub 2021. PMID: 33746047.
- Pan K, Franke AJ, Skelton WP, Bishnoi R, Shah C, Dang NH, Alquadan K. Reduction of Immunosuppression for Post-transplant Lymphoproliferative Disorder (PTLD): A single-center experience of allograft survival outcomes. Leuk Lymphoma 62(5):1123-1128, 2021. e-Pub 2020. PMID: 33327817.
- Waheed N, Fradley MG, DeRemer DL, Mahmoud A, Shah CP, Langaee TY, Lipori GP, March K, Pepine CJ, Cooper-DeHoff RM, Wu Y, Gong Y. Newly Diagnosed Cardiovascular Disease in Patients Treated with Immune Checkpoint Inhibitors: A retrospective analysis of patients at an academic tertiary care center. Cardiooncology 7(1):10, 2021. e-Pub 2021. PMID: 33736707.
- Hong YR, Xie Z, Turner K, Datta S, Bishnoi R, Shah C. Utilization Pattern of Computed Tomographic Colonography in the United States: Analysis of the U.S. National Health Interview Survey. Cancer Prev Res (Phila) 14(1):113-122, 2021. e-Pub 2020. PMID: 32938642.
- Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, Farhadfar N. Real-world Experience of Carfilzomib-associated Cardiovascular Adverse Events: SEER-Medicare data set analysis. Cancer Med 10(1):70-78, 2021. e-Pub 2020. PMID: 33169938.
- Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, Cornell RF, Baz RC, Fradley MG, Waheed N, DeRemer DL, Yuan L, Langaee T, March K, Pepine CJ, Moreb JS, Gong Y. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated with Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a multi-omics integrative analysis. Front Cardiovasc Med 8:645122, 2021. e-Pub 2021. PMID: 33996940.
- address: jeremywarner@vumcorg CACCE, Cancer Consortium CA. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell 38(6):761-766, 2020. e-Pub 2020. PMID: 33176160.
- Bishnoi R, Shah C, Blaes A, Bian J, Hong YR. Cardiovascular Toxicity in Patients Treated with Immunotherapy for Metastatic Non-small Cell Lung Cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC. Lung Cancer 150(None):172-177, 2020. e-Pub 2020. PMID: 33186859.
- Du X, Min J, Shah CP, Bishnoi R, Hogan WR, Lemas DJ. Predicting In-hospital Mortality of Patients with Febrile Neutropenia using Machine Learning Models. Int J Med Inform 139(None):104140, 2020. e-Pub 2020. PMID: 32325370.
- Shah C, Hong YR, Bishnoi R, Jones D, Huo J. Utilization of Antineoplastic Agents and Medicare Spending in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer Between 2001 and 2013. JCO Oncol Pract 16(7):e610-e621, 2020. e-Pub 2020. PMID: 32074011.
- Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, Shah C. Clinical Impact of COVID-19 on Patients with Cancer (CCC19): A cohort study. Lancet 395(10241):1907-1918, 2020. e-Pub 2020. PMID: 32473681.
- Lutfi F, Bishnoi R, Patel VJ, Elfasi A, Setteducato M, Zhang S, Shah CP, Kurian S, Kamath C, Kim DJ, Zumberg MS, Murphy M. Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion. Cureus 12(5):e8339, 2020. e-Pub 2020. PMID: 32617214.
- Bishnoi R, Minish J, Franke AJ, Skelton WP, Shah CP, Wang Y, Dang NH. Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder. Cureus 12(2):e6912, 2020. e-Pub 2020. PMID: 32190467.
- Shah C, Hong YR, Bishnoi R, Ali A, Skelton WP, Dang LH, Huo J, Dang NH. Impact of DPP4 Inhibitors in Survival of Patients with Prostate, Pancreas, and Breast Cancer. Front Oncol 10(None):405, 2020. e-Pub 2020. PMID: 32296640.
- Shah CP, Mramba LK, Bishnoi R, Unnikrishnan A, Duff JM, Chandana SR. Survival Trends of Metastatic Small Intestinal Neuroendocrine Tumor: A population-based analysis of SEER database. J Gastrointest Oncol 10(5):869-877, 2019. PMID: 31602324.
- Bishnoi R, Hong YR, Shah C, Ali A, Skelton WP, Huo J, Dang NH, Dang LH. Dipeptidyl Peptidase 4 Inhibitors as Novel Agents in Improving Survival in Diabetic Patients with Colorectal Cancer and Lung Cancer: A surveillance epidemiology and endpoint research Medicare study. Cancer Med 8(8):3918-3927, 2019. e-Pub 2019. PMID: 31124302.
- Ali A, Fuentes A, Skelton WP, Wang Y, McGorray S, Shah C, Bishnoi R, Dang LH, Dang NH. A Multi-center Retrospective Analysis of the Effect of DPP4 Inhibitors on Progression-free Survival in Advanced Airway and Colorectal Cancers. Mol Clin Oncol 10(1):118-124, 2019. e-Pub 2018. PMID: 30655986.
- Shah C, Bishnoi R, Wang Y, Zou F, Bejjanki H, Master S, Moreb JS. Efficacy and Safety of Carfilzomib in Relapsed and/or Refractory Multiple Myeloma: Systematic review and meta-analysis of 14 trials. Oncotarget 9(34):23704-23717, 2018. e-Pub 2018. PMID: 29805768.
- Shah C, Gong Y, Szady A, Sun Q, Pepine CJ, Langaee T, Lucas AR, Moreb JS. Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural history and risk factors. Cardiovasc Toxicol 18(2):184-191, 2018. PMID: 29022233.
- Bejjanki H, Mramba LK, Beal SG, Radhakrishnan N, Bishnoi R, Shah C, Agrawal N, Harris N, Leverence R, Rand K. The Role of a Best Practice Alert in the Electronic Medical Record in Reducing Repetitive Lab Tests. Clinicoecon Outcomes Res 10(None):611-618, 2018. e-Pub 2018. PMID: 30323637.
- Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival Differences Among Patients with Hepatocellular Carcinoma Based on the Stage of Disease and Therapy Received: Pre and post Sorafenib era. J Gastrointest Oncol 8(5):789-798, 2017. PMID: 29184682.
- Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH. EUS-FNA for Pancreatic Neuroendocrine Tumors: A tertiary cancer center experience. Dig Dis Sci 57(3):791-800, 2012. e-Pub 2011. PMID: 21964743.
- Shah CP, Shienbaum G, Shields CL, Eagle RC, Lally S, Shields JA. Neovascular Glaucoma as the Presenting Sign of Metastatic Small Cell Lung Carcinoma. Retin Cases Brief Rep 5(1):26-9, 2011. PMID: 25389677.
Other Articles
- Mendia A, Shah CP, Grajo JR, Yachnis A, Yeung A, Cardenas-Goicoechea J, Murphy M Orbital Metastasis of Squamous Cell Cervical Cancer: A case report and review of literature. Gynecol Oncol Rep 35:100689, 2021. PMID: 33385055.
- Shah CP, Delaune J, Mandernach MW Acquired Von Willebrand Syndrome in Association with Multiple Myeloma: Remission after stem cell transplant. BMJ Case Rep 14(1), 2021. PMID: 33504531.
- De Leo EK, Shah CP, Grajo JR, Liu X, Parekh H Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy. Cureus 13(1):e12899, 2021. PMID: 33654584.
- Shah CP, Moreb JS Cardiotoxicity due to Targeted Anticancer Agents: A growing challenge. Ther Adv Cardiovasc Dis 13(None):1753944719843435, 2019. PMID: 30995890.
- Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, Zou F, Moreb JS Cardiotoxicity Associated with Carfilzomib: Systematic review and meta-analysis. Leuk Lymphoma 59(11):2557-2569, 2018. PMID: 29465266.
- Turaka K, Shields CL, Shah CP, Say EA, Shields JA Bilateral Uveal Melanoma in an Arc Welder. Graefes Arch Clin Exp Ophthalmol 249(1):141-4, 2011. PMID: 20853114.
Patient Reviews
CV information above last modified October 29, 2024